Ultimovacs ASA

Oslo Stock Exchange ULTI.OL

Ultimovacs ASA Price to Earnings Ratio (P/E) on January 14, 2025: -0.34

Ultimovacs ASA Price to Earnings Ratio (P/E) is -0.34 on January 14, 2025, a 98.57% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.

Ultimovacs ASA 52-week high Price to Earnings Ratio (P/E) is -0.28 on October 09, 2024, which is 19.89% above the current Price to Earnings Ratio (P/E).
Ultimovacs ASA 52-week low Price to Earnings Ratio (P/E) is -28.31 on February 20, 2024, which is -8,111.21% below the current Price to Earnings Ratio (P/E).
Ultimovacs ASA average Price to Earnings Ratio (P/E) for the last 52 weeks is -4.41.

Key data

Date	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield

Oslo Stock Exchange: ULTI.OL

Ultimovacs ASA

CEO	Dr. Carlos de Sousa
IPO Date	June 3, 2019
Location	Norway
Headquarters	Ullernchausséen 64
Employees	17
Sector	Health Care
Industries Pharmaceuticals Biotechnology Vaccines

Description

Ultimovacs ASA, a pharmaceutical company, develops immunotherapies for cancers. Its lead product candidate is UV1, a peptide-based vaccine that induces T cell response against the universal cancer antigen telomerase. The company was incorporated in 2011 and is headquartered in Oslo, Norway.

Key trends

Past 5 years